Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytomegalovirus pp65-lysosome-associated membrane glycoprotein ribonucleic acid-pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Duke University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
**Cytomegalovirus pp65-lysosome-associated membrane glycoprotein ribonucleic acid-pulsed dendritic cell vaccine** is an autologous dendritic cell-based therapeutic cancer vaccine developed primarily at Duke University for glioblastoma and studied in both adult and pediatric malignant brain tumors. The product is generated from patient-derived mature dendritic cells electroporated or pulsed with messenger RNA encoding a fusion of the human cytomegalovirus phosphoprotein 65 antigen and lysosome-associated membrane glycoprotein 1, a design intended to enhance antigen processing and presentation through major histocompatibility complex pathways. After intradermal administration, often with granulocyte-macrophage colony-stimulating factor as an admixed adjuvant, the vaccine is intended to prime and expand CMV pp65-specific antitumor T-cell responses against CMV pp65-expressing glioma cells. It is a personalized biologic cell therapy and therapeutic vaccine rather than a prophylactic antiviral vaccine.
- Other names
- cytomegalovirus pp65-lysosome-associated membrane glycoprotein ribonucleic acid-pulsed dendritic cell vaccineCMV pp65-LAMP mRNA-pulsed dendritic cell vaccinepp65-LAMP mRNA-pulsed dendritic cell vaccinepp-65-LAMP mRNA-pulsed dendritic cell vaccinepp 65-LAMP mRNA-pulsed dendritic cell vaccineautologous pp65-LAMP mRNA-pulsed dendritic cell vaccinecytomegalovirus pp65 dendritic cell vaccine
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on cytomegalovirus pp65-lysosome-associated membrane glycoprotein ribonucleic acid-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytomegalovirus pp65-lysosome-associated membrane glycoprotein ribonucleic acid-pulsed dendritic cell vaccine.